Senior Lecturer in Respiratory Medicine @OfficialUoM Precision medicine in #COPD & #AECOPD, Clinical #Trials, #Guidelines, #EBM.
Manchester, England
Joined June 2011
- Tweets862
- Following1K
- Followers845
- Likes1.5K
Pinned Tweet
Thank you to the @HCPLiveNews editorial team and @ChelsieDerman for the opportunity to discuss this work.
💡In a FLAME post-hoc analysis we found 3-month withdrawal effects on COPD exacerbations after ICS or LAMA discontinuation.
🔗 hcplive.com/view/copd-drug-w…
MathioudakisAG retweeted
📙 The ERS Bookshop is open until Tuesday!
Head to the World Village to browse and purchase the latest titles, including the recently-published ERS Monographs “Thoracic Ultrasound” and “Obstructive and Central Sleep Apnoea” 📚
@ERSpublications
MathioudakisAG retweeted
Online Now: Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine dlvr.it/TT7ZfV
MathioudakisAG retweeted
Guidelines in brief: Core outcome set for trials evaluating the management of community-acquired and nosocomial pneumonia.
Access the full guideline (and additional content) via the ERS Respiratory Channel:channel.ersnet.org/channel-3…
Watch the video 👇
MathioudakisAG retweeted
"Deprioritising clinical academic salaries and pensions impacts an already diminishing consultant academic workforce and risks further irretrievable damage"
Letter to @educationgovuk @DHSCgovuk from Association of British Neurologists @BMA_Academics
theabn.org/news/732332/Withd…
MathioudakisAG retweeted
Just published: our review showing the heterogeneity of outcomes reported in COPD clinical trials
This underlines the need for the @EuroRespSoc core outcome set for COPD pharmacotherapy trials, which I'm co-chairing with @MathioudakisAG and @LiesLahousse
publications.ersnet.org/cont…
MathioudakisAG retweeted
Responding to @officestudents guidance from the Secretary of State for Education setting out funding for 2026-27 for universities that imposes cuts to funding for medical academics: bma.org.uk/bma-media-centre/…
MathioudakisAG retweeted
The European Respiratory Journal impact factor, released today, has increased to 23.8, its highest ever level outside of the COVID-19 pandemic.
We are incredibly proud of the high scientific impact of the ERJ @ERSpublications and very grateful to authors, reviewers, our outstanding publication office team and our outstanding editors.
Respiratory Journal IFs
Lancet Resp 34.7
ERJ 23.8
Journal of thoracic Oncology 23.3
AJRCCM 21.7
ERR 10.8
CHEST 9.8
Thorax 9.1
@EuroRespSoc @donsin4
MathioudakisAG retweeted
🚭 ERS urges other countries to follow the example of the United Kingdom (UK) after it announced a generational sales ban on tobacco.
Read more: ersnet.org/news-and-features…
MathioudakisAG retweeted
@victoriachgr Dr Victoria Chatzimavridou gave us a fascinating run through of her work on pelvic insufficiency fractures caused by radiotherapy. #BoneUp #ECTS26
I’m seeing more and more referrals like this to the clinic
🚨 Clinical academics undertake years of additional research training — but this is not recognised in NHS consultant pay progression.
This creates a structural inconsistency → ~£72,000–£81,000 lifetime loss per research year during training.
📖academic.oup.com/qjmed/advan…
🎯At a time when the UK is seeking to strengthen its life sciences sector and reverse declining numbers of medical academics, pay arrangements should support — not discourage — doctors from undertaking research training.
Big thanks to @TheBMA @BMA_Academics @gibb_jonathan @DocStrain for sharing these findings with @wesstreeting and other stakeholders. We hope this inconsistency will now be reviewed and addressed.
MathioudakisAG retweeted
ERR: This meta-analysis (111 studies) quantifies viral prevalence in acute/stable asthma in children and adults, and highlights links between specific viruses and acute asthma severity. PCR alone may be limited in identifying viral acute asthma triggers. bit.ly/4ts91DT
MathioudakisAG retweeted
This article in @AnnalsofIM highlights ethical problems in stopping trials early for benefit: seriously inflated overestimates of treatment effect violates ethical requirements of scientific validity and social value and leads to misguided patient choices.
pubmed.ncbi.nlm.nih.gov/1757…
Great to see our work featured by @ChestPhysician .
Discontinuing LAMA or ICS in COPD is not neutral—there is a transient spike in exacerbation risk (~2x) for 3 months, consistent with withdrawal effects.
chestphysician.org/effects-o…
#LAMA and #ICS are both associated with significant withdrawal effects.
Important implications for practice, adherence, and trial interpretation.
Here is our independent post-hoc analysis of FLAME trial: thorax.bmj.com/content/early…
MathioudakisAG retweeted
Redundancies, retirement and funding cuts threaten the UK’s global standing in medical research as fewer NHS doctors can secure posts as clinical academics. Government inaction to address this loss of talent risks harming patient care and the UK’s economic future.
The number of medical academics has flatlined. This situation is threatening the UK’s global standing in medical research as fewer NHS consultants can secure posts as clinical academics.
Governments must act now.
Read about the crisis The Times
thetimes.com/article/be782e7…
